Abstract:PURPOSE To explore and evaluate the protective effect of erythropoietin (EPO) on retinal cells of chemically induced diabetic rats after EPO was injected intravitreally at the onset of diabetes. METHODS Diabetes was induced in Sprague-Dawley rats by intraperitoneal injection of streptozotocin (STZ). At the onset of diabetes, a single intravitreal injection of EPO (0.05-200 ng/eye) was performed. In the following 6 weeks, the blood retinal barrier (BRB) was evaluated by Evans blue permeation (EBP). Retinal cell death in different layers was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The retinal thickness and cell counts were examined at the light microscopic level. Electron microscopy (EM) was used to scrutinize retinal vascular and neuronal injury. Neurosensory retinas of normal and diabetic rats were used as the sources of reverse transcription-polymerase chain reaction (RT-PCR) and Western blot for the detection of EPO, EPO receptor (EpoR), and products of the extracellular signal-regulated kinase (ERK) and the signal transducers and activators of transcription 5 (STAT5) pathways. The distribution of EpoR in retinal layers was demonstrated by immunohistochemistry (IHC). RESULTS In the diabetic rats, BRB breakdown was detected soon after the onset of diabetes, peaked at 2 weeks, and reached a plateau at 2 to 4 weeks. The number of TUNEL-positive cells increased in the neurosensory retina, especially, the outer nuclear layer (ONL) at 1 week after diabetes onset and reached a peak at 4 to 6 weeks. The retinal thickness and the number of cells in the ONL were reduced significantly. EM observations demonstrated vascular and photoreceptor cell death starting soon after the onset of diabetes. All these changes were largely prevented by EPO treatment. Upregulation of EpoR in the neurosensory retina was detected at both the transcriptional and protein levels 4 to 8 weeks after the onset of diabetes, whereas, the endogenous EPO levels of neurosensory retinas were essentially unchanged during the same period observed. In EPO-treated diabetic groups, EpoR expression remained at upregulated levels. Within 2 weeks of the onset of diabetes, activation of the ERK but not the STAT5 pathway was detected in the diabetic retina treated with EPO. CONCLUSIONS These data demonstrate that apoptosis is an major contributor to neuronal cell death in the early course of diabetic retinopathy (DR). The upregulation of EpoR may be a compensatory response of retinal cells and tissue to diabetic stresses. The EPO/EpoR system as a maintenance-survival mechanism of retinal neurons responds to the insults of early diabetes other than ischemia. The protective function of EPO/EpoR at the least acts through the EpoR-mediated ERK pathway. Exogenous EPO administration by intravitreal injection in early diabetes may prevent retinal cell death and protect the BRB function. Therefore, this is a novel approach for treatment of early DR.

Erythropoietin Exerts a Neuroprotective Function Against Glutamate Neurotoxicity in Experimental Diabetic Retina.

Erythropoietin Protects Primary Cultures of Rat Cortical Neurons from Hypoxia-Induced Toxicity Through Attenuating Both Glutamate Release and NMDA Receptor Evoked Neurotoxicity Pathway.

Intravitreal Injection of Erythropoietin Protects Both Retinal Vascular and Neuronal Cells in Early Diabetes

Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy

Promotion of Neurite Outgrowth and Protective Effect of Erythropoietin on the Retinal Neurons of Rats

Erythropoietin (EPO) protects against high glucose-induced apoptosis in retinal ganglional cells

Erk- And Akt-Dependent Neuroprotection By Erythropoietin (Epo) Against Glyoxal-Ages Via Modulation Of Bcl-Xl, Bax, And Bad

Carbamylated Erythropoietin Mediates Retinal Neuroprotection in Streptozotocin-Induced Early-Stage Diabetic Rats

Erythropoietin Protects Outer Blood-Retinal Barrier in Experimental Diabetic Retinopathy by Up-Regulating ZO-1 and Occludin

Erythropoietin Protects Müller Cells Through Maintaining Its Expression of Glutamate-Aspartate Transporter

Erythropoietin Protects Retinal Cells In Diabetic Rats Through Upregulating Znt8 Via Activating Erk Pathway And Inhibiting Hif-1 Alpha Expression

Anti-Vegf Effects of Intravitreal Erythropoietin in Early Diabetic Retinopathy

Exenatide Prevents High-Glucose-induced Damage of Retinal Ganglion Cells Through a Mitochondrial Mechanism

Neuroprotective properties of erythropoietin on neuro-retinopathy

The Influence of Erythropoietin to the Ultrastructure of Retinal Neurons and Content of Retinal Glutamate in the Early Stage Diabetic Rats

Erythropoietin Maintains VE-cadherin Expression and Barrier Function in Experimental Diabetic Retinopathy Via Inhibiting VEGF/VEGFR2/Src Signaling Pathway

Neuroprotective Effect of Recombinant Human Erythropoietin on Retinal Ischemia Reperfusion Induced Retinal Neuron Injury in Rats

Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina

Intravitreal Injection of Erythropoietin Sustained-Release Microspheres Protects Damaged Retinal Ganglion Cells in Rats

Up-regulated Endogenous Erythropoietin/erythropoietin Receptor System and Exogenous Erythropoietin Rescue Retinal Ganglion Cells after Chronic Ocular Hypertension.

Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo